ranQ
ranQ
ranQ
DirectoryIndustriesPlacesKnowledgeComparisonsSoon
Sign inCheck visibility
ranQHSG Startup LabelRecognised by the
HSG Startup Label

The leading AI company directory, built to boost AI visibility.

DEENFRIT
Product
  • Pricing
  • Directory
  • Industries
  • Trust Score
Company
  • About
  • Partner program
  • Contact
  • Legal
© 2026 cohaga AG · All Rights Reserved · St. Gallen, Switzerland · Imprint747,212 companies indexed · Last updated: today
DirectoryIndustryPharmaceutical companyBaselMonte Rosa Therapeutics AG
Monte Rosa Therapeutics AG Logo
Verified· 3 sourcesTrust Score
Summary

About the company

Monte Rosa Therapeutics AG develops pharmaceutical drug candidates using a molecular glue degrader platform designed to selectively eliminate disease-related proteins. Its research and development focuses on cancer, immunology, inflammatory and cardiometabolic diseases.

AI-generated
Offering

Products & services

Industry:Pharmaceutical company
✓ Offered
LeadhubOutbound Leads by COHAGA

Looking for direct email addresses and phone numbers?

Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.

Discover Leadhub
4.1/5

Monte Rosa Therapeutics AG

4
Development of molecular glue degraders
Development of molecular glue degraders for targeted protein degradation therapies, including preclinical and clinical programs against oncology, immunology and inflammatory diseases.
Oncology programs
Oncology programs with oral, selective MGD candidates against GSPT1 and CCNE1/CDK2, including studies and preclinical development in castration-resistant prostate cancer and CCNE1-amplified tumours.
Immunology and inflammation programs
Immunology and inflammation programs with MGD candidates against VAV1 and NEK7 for immune-mediated and IL-1β/NLRP3-driven diseases, spanning clinical, preclinical and collaborative development.
Drug discovery and development partnerships
Collaborations and licensing agreements to discover and develop MGD candidates against targets in cancer, neurological and immune-mediated diseases.
Trust & reputation

ranQ Trust Score of Monte Rosa Therapeutics AG: 4.1 out of 5.0

Trust Score4.1/ 5.0

High

x

Data basis 58% · As of November 2026

Without public customer reviews the score stays capped.

Monte Rosa Therapeutics AG has no value in the Reputation area of the ranQ Trust Score because no data is available. The area carries 42% of the weighting and drops out of the calculation for this profile; it does not lower the score, only the reported data basis.
x
CriterionValueWeight
  • Review quality: No data point — the criterion is taken out of the weighting and does not lower the score.—24%
  • Review volume: No data point — the criterion is taken out of the weighting and does not lower the score.—10%
  • Review recency: No data point — the criterion is taken out of the weighting and does not lower the score.—8%
Monte Rosa Therapeutics AG scores 83.4 out of 100 points in the Substance area of the ranQ Trust Score. This area carries 28% of the weighting.
x
CriterionValueWeight
  • Establishment: Years since founding or brand launch, logarithmic. The maximum is reached at 15 years.79.212%
  • Company size: The headcount band, researched by ranQ or stated by the company. It is scored in steps rather than by head count, because the data only provides bands.82.07%
Monte Rosa Therapeutics AG scores 85.0 out of 100 points in the Identity area of the ranQ Trust Score. This area carries 22% of the weighting.
x
CriterionValueWeight
  • Verification: Official register entry (commercial register with UID or professional-body record, 55 points), confirmed domain (20 points) and confirmed ranQ profile (up to 25 points, depending on completeness).85.022%
Monte Rosa Therapeutics AG scores 60.0 out of 100 points in the Visibility area of the ranQ Trust Score. This area carries 8% of the weighting.
x
CriterionValueWeight
  • Website authority: Ahrefs' Domain Rating measures, on a scale of 0 to 100, how strongly a website is linked from other websites. For Swiss SMEs the range up to 40 is typical; the maximum is reached at 35.100.04%
  • Media authority: Quality and number of editorial mentions, weighted by the importance of the source, plus the recency of the latest high-quality mention.20.04%
Qualifications+0.00

Monte Rosa Therapeutics AG reaches a ranQ Trust Score of 4.1 out of 5.0 — rated «High». No public customer reviews are available for this provider; the rating is based on the remaining criteria. The data basis is 58%, so the score is backed by part of the criteria. As of November 2026.

The Trust Score cannot be bought and is calculated from publicly verifiable data.

Press

Media

October 28, 2024Media
Monte-Rosa Therapeutics enters billion-dollar partnership with Novartis
startupticker.ch
June 25, 2021Media
Monte Rosa Therapeutics raises USD222 million in successful IPO
startupticker.ch

Knowledge

No knowledge articles yet

Once Monte Rosa Therapeutics AG has claimed this profile, we'll publish editorial articles and case studies here together.

Get started
Comparisons

Monte Rosa Therapeutics AG in comparison

Soon

Industry comparisons are coming soon

We're preparing industry comparisons that rank Monte Rosa Therapeutics AG by reviews, experience and specialisations.

Is this your company?

Claim the company profile of Monte Rosa Therapeutics AG to make its contact details visible. With a plan we additionally create and publish industry comparisons, articles and much more.

Secure profile

Location

Klybeckstrasse 191
4057 Basel

At a glance

Legal form
Corporation
UID
CHE-405.675.696
Founded
2018 · 8 years
Last commercial register change
March 13, 2026
Employees
21 to 50
Legal form: Graded by liability and disclosure. The weight is kept small: a sole proprietorship is not a dubious company, it is just liable differently.
100.0
6%
  • Branch offices: Branch offices linked in the commercial register. Having none is normal and costs no points.70.03%
  • Full methodology

    Similar companies

    ST
    Skyhawk Therapeutics Europe GmbH
    Basel
    MB
    Myria Biosciences AG
    Basel
    PT
    ProPharma Therapeutics GmbH
    Basel
    BA
    BioVersys AG
    Basel
    LT
    LifeMine Therapeutics (Switzerland) GmbH
    Basel
    RM
    Revolution Medicines Switzerland GmbH
    Basel
    AT
    Aukera Therapeutics AG
    Basel
    NP
    Nxera Pharma CH Services GmbH
    Basel